{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T20:11:47Z","timestamp":1651695107183},"reference-count":12,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Jpn. Soc. Intern. Med","J. Jpn. Soc. Intern. Med."],"published-print":{"date-parts":[[2014]]},"DOI":"10.2169\/naika.103.978","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T22:09:40Z","timestamp":1428617380000},"page":"978-982","source":"Crossref","is-referenced-by-count":0,"title":["The Pathology and New Treatment of ADPKD"],"prefix":"10.2169","volume":"103","author":[{"given":"Satoru","family":"Muto","sequence":"first","affiliation":[{"name":"Department of Urology, Teikyo University, School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[{"name":"Department of Urology, Juntendo University, Graduate School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Yamaguchi T, et al: Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30: 703-709, 1997.","DOI":"10.1016\/S0272-6386(97)90496-0"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Yamaguchi T, et al: Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP dependent growth-stimulated phenotype. J Biol Chem 279: 40419-40430, 2004.","DOI":"10.1074\/jbc.M405079200"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ward CJ, et al: Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 102-108, 2008.","DOI":"10.1681\/ASN.2007060688"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Ho TA, et al: Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Kidney Int 82: 1121-1129, 2012.","DOI":"10.1038\/ki.2012.225"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Gattone VH 2nd, et al: Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9: 1323-1326, 2003.","DOI":"10.1038\/nm935"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Wang X, et al: Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol 16: 846-851, 2005.","DOI":"10.1681\/ASN.2004121090"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Torres VE, et al: Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363-364, 2004.","DOI":"10.1038\/nm1004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Irazabal MV, et al: Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. Kidney Int 80: 295-301, 2011.","DOI":"10.1038\/ki.2011.119"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Torres VE, et al: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367: 2407-2418, 2012.","DOI":"10.1056\/NEJMoa1205511"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ruggenenti P, et al: Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206-216, 2005.","DOI":"10.1111\/j.1523-1755.2005.00395.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hogan MC, et al: Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol 21: 1052-1061, 2010.","DOI":"10.1681\/ASN.2009121291"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Caroli A, et al: Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol 5: 783-789, 2010.","DOI":"10.2215\/CJN.05380709"}],"container-title":["Nihon Naika Gakkai Zasshi"],"original-title":["\u591a\u767a\u6027\u56a2\u80de\u814e\u306e\u75c5\u614b\u3068\u6cbb\u7642\uff1a\u65b0\u305f\u306a\u5c55\u958b"],"language":"en","deposited":{"date-parts":[[2022,5,4]],"date-time":"2022-05-04T19:41:24Z","timestamp":1651693284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/naika\/103\/4\/103_978\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2169\/naika.103.978","relation":{},"ISSN":["0021-5384","1883-2083"],"issn-type":[{"value":"0021-5384","type":"print"},{"value":"1883-2083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}